Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Julie Eastland is recorded as CEO and Board Member at Zentalis Pharmaceuticals, Inc. (ZNTL) and Board Member at Lantheus Holdings, Inc. (LNTH). Zentalis Pharmaceuticals, Inc. reported in an 8-K filed November 13, 2024 that Julie Eastland was appointed President, effective November 13, 2024. Zentalis Pharmaceuticals, Inc. reported in an 8-K filed November 13, 2024 that Julie Eastland was appointed Class I director, effective November 13, 2024. Zentalis Pharmaceuticals, Inc. reported in an 8-K filed November 13, 2024 that Julie Eastland was appointed Chief Executive Officer, effective November 13, 2024. Equibles holds 4 filed executive changes naming Julie Eastland; each is listed under recent activity with its source filing. The proxy statement of Zentalis Pharmaceuticals, Inc. reports total compensation of $1,300,731 for Julie Eastland in fiscal 2025, including a base salary of $700,000. Disclosed compensation is on record for 2 fiscal years. Julie Eastland has spoken on 3 investor events across 1 company, most recently for Zentalis Pharmaceuticals, Inc. on September 8, 2026.
“On November 12, 2024, the Board of Directors (the "Board") of Zentalis Pharmaceuticals, Inc. (the "Company") appointed Julie Eastland as Chief Executive Officer, President and a Class I director of the Company with an initial term scheduled to expire at the Company's 2027 Annual Meeting of Stockholders, in each case effective November 13, 2024 (the "Transition Date").”
“On November 12, 2024, the Board of Directors (the "Board") of Zentalis Pharmaceuticals, Inc. (the "Company") appointed Julie Eastland as Chief Executive Officer, President and a Class I director of the Company with an initial term scheduled to expire at the Company's 2027 Annual Meeting of Stockholders, in each case effective November 13, 2024 (the "Transition Date").”
Summary generated from SEC filings and earnings-call records held by Equibles.
Recorded current and former roles; source labels appear when available.
2024-11-13–present
2024-01-01–present
2024-01-01–present
Start not stated–present
Recorded roles and call appearances connecting this person to public companies.
CEO, Board Member
2024-01-01–present
Other people whose current roles at this company are on record from its filings.
Other people whose current roles at this company are on record from its filings.
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Zentalis Pharmaceuticals, Inc. (ZNTL) | President and Chief Executive Officer | $700,000 | $1,300,731 |
| 2024 | Zentalis Pharmaceuticals, Inc. (ZNTL) | President and Chief Executive Officer | $94,231 | $8,188,909 |
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.
